LA JOLLA, CA, AND NASHVILLE, TN January 13, 2010 The Scripps Research Institute and Vanderbilt University have formed a partnership to advance science at the interface of chemistry and medicine, the institutions announced today.
The Human Chemical Sciences Institute will encompass research and training activities at Scripps Research on its San Diego, California, and Jupiter, Florida, campuses, and at the Vanderbilt Institute for Chemical Biology (VICB) and Vanderbilt University School of Medicine in Nashville, Tennessee.
Special emphasis will be devoted to the areas of drug discovery, personalized medicine and metabolomics, the latter referring to the study of small molecule metabolites that could lead to diagnostic and therapeutic biomarkers.
"The chemical sciences provide the basis for current understanding of human physiology, pharmacology and drug discovery," said Scripps Research President Richard A. Lerner, M.D. "Yet there remains a gulf between academic research in chemistry and medical practice. The time is right for a new initiative that seeks to accelerate the understanding of human chemistry in health and disease."
"The goal of the Human Chemical Sciences Institute is to impact medical care through a chemistry-focused view of the human metabolic state, disease and the effects of treatment," said Jeffrey Balser, M.D., Ph.D., vice chancellor for health affairs and dean of Vanderbilt University School of Medicine.
The new institute will combine Scripps Research's expertise as a powerhouse in synthetic and bioorganic chemistry, the strength of both institutions at the interface of chemistry and biology, and Vanderbilt's recognized leadership in drug discovery, genomics, bioinformatics, and medical systems innovation. Seed funding from both Scripps Research and Vanderbilt will be used to promote cross-institutional and cross-disciplinary research partnerships that capitalize upon these strengths.
The three focus areas will
|Contact: Mika Ono|
Scripps Research Institute